Tivozanib Has Efficacy in Advanced Renal Cell Carcinoma Post-ICI Therapy
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 20, 2024 -- For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI), tivozanib has efficacy, according to a study published online Sept. 13 in The Lancet to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
Toni K. Choueiri, M.D., from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, and colleagues examined the outcomes of tivozanib-nivolumab versus tivozanib monotherapy in patients with mRCC who progressed following one or two lines of therapy in the post-ICI setting in a randomized, phase 3 trial. Patients were randomly allocated to tivozanib plus nivolumab or tivozanib monotherapy (171 and 172 patients, respectively) and were followed for a median of 12.0 months.
The researchers found that median progression-free survival was 5.7 and 7.4 months with tivozanib-nivolumab and tivozanib monotherapy, respectively, which was not significantly different. Among 244 patients with ICI as immediate prior therapy, median progression-free survival was 7.4 and 9.2 months with tivozanib-nivolumab and tivozanib monotherapy, respectively. With non-ICI as the most recent therapy, median progression-free survival was lower, with no significant difference seen between the groups (both 3.7 months). Serious adverse events occurred in 32 and 37 percent of patients who received tivozanib-nivolumab and tivozanib monotherapy, respectively.
"These results demonstrated clinical activity of tivozanib monotherapy as a second line treatment option, and rechallenging with nivolumab in the setting of prior exposure to ICI is not warranted," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Aveo Pharmaceuticals, which manufactures tivozanib and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Systemic Immune-Inflammation Index Tied to Mortality in CKD
TUESDAY, Sept. 24, 2024 -- There is a J-shaped association between systemic immune-inflammation index (SII) levels and all-cause mortality in patients with chronic kidney disease...
Homelessness Linked to ESKD, Death in Veterans With Incident CKD
FRIDAY, Sept. 20, 2024 -- For veterans with incident chronic kidney disease (CKD), a history of homelessness is associated with an increased risk for end-stage kidney disease...
Dementia Diagnoses Up in Individuals With Acute Kidney Injury
THURSDAY, Sept. 5, 2024 -- Individuals with acute kidney injury (AKI) have an increased risk for receiving a clinical diagnosis of dementia, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.